Lexaria Bioscience Corp.
LEXX
$0.58
-$0.10-14.96%
NASDAQ
| 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 52.04% | 49.85% | 29.95% | 77.65% | 105.35% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 52.04% | 49.85% | 29.95% | 77.65% | 105.35% |
| Cost of Revenue | -43.75% | -43.75% | -84.57% | -86.83% | -84.76% |
| Gross Profit | 53.04% | 50.96% | 35.12% | 90.59% | 136.00% |
| SG&A Expenses | 7.25% | 52.60% | 79.14% | 49.33% | 30.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 99.00% | 141.75% | 76.40% | 26.84% | -6.56% |
| Operating Income | -102.79% | -150.04% | -80.00% | -24.42% | 10.49% |
| Income Before Tax | -105.06% | -134.05% | -71.74% | -19.61% | 13.47% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -105.06% | -134.05% | -71.74% | -19.61% | 13.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -27.82% | -52.83% | -63.84% | -73.75% | -72.12% |
| Net Income | -105.37% | -134.87% | -72.50% | -20.23% | 13.05% |
| EBIT | -102.79% | -150.04% | -80.00% | -24.42% | 10.49% |
| EBITDA | -103.97% | -155.55% | -83.67% | -26.26% | 9.63% |
| EPS Basic | -44.43% | -40.50% | 17.83% | 43.62% | 55.69% |
| Normalized Basic EPS | -44.00% | -53.18% | 13.55% | 41.18% | 54.29% |
| EPS Diluted | -44.43% | -40.50% | 17.83% | 43.62% | 55.69% |
| Normalized Diluted EPS | -44.00% | -53.18% | 13.55% | 41.18% | 54.29% |
| Average Basic Shares Outstanding | 45.91% | 63.21% | 85.50% | 92.88% | 86.70% |
| Average Diluted Shares Outstanding | 45.91% | 63.21% | 85.50% | 92.88% | 86.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |